A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety, tolerability, antiviral effects, and
pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.